Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Reviews in the Neurosciences

Volumn 27, Issue 7, 2016, Pages 689-711

  Li, Yanwei ^a,b   Li, Lin ^a   Hölscher, Christian ^a,c  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b Shaoyang Medical College   (China)

^c LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; DPP IV inhibitors; glucagon like peptide 1; glucose dependent insulinotropic polypeptide; incretin; insulin resistance; Parkinson's disease; type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INCRETIN; ANTIDIABETIC AGENT; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; PEPTIDE; VENOM;

AGING; ALZHEIMER DISEASE; ARTICLE; CELL PROLIFERATION; CORE TEMPERATURE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; LONG TERM POTENTIATION; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; NEURODEGENERATIVE DISEASES; PEPTIDES; VENOMS;

EID: 84991355119     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2016-0018     Document Type: Article

References (266)

1. Abbas, T., Faivre, E., and Holscher, C. (2009). Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205, 265-271.
2. Abbott, C.R., Monteiro, M., Small, C.J., Sajedi, A., Smith, K.L., Parkinson, J.R., Ghatei, M.A., and Bloom, S.R. (2005). The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044, 127-131.
3. Abdelsalam, R.M. and Safar, M.M. (2015). Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J. Neurochem. 133, 700-707.
4. Anderson, R., Hayes, J., and Stephens, J.W. (2016). Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opin. Drug Metab. Toxicol. 12, 467-473.
5. Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., and Watada, H. (2010). Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59, 1030-1037.
6. Ashraf, G.M., Greig, N.H., Khan, T.A., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I.A., Zaidi, S.K., Akram, M., Jabir, N.R., et al. (2014). Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets 13, 1280-1293.
7. Athauda, D. and Foltynie, T. (2016). The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov. Today. DOI: 10.1016/j. drudis.2016.01.013.
8. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013a). Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736.
9. Aviles-Olmos, I., Limousin, P., Lees, A., and Foltynie, T. (2013b). Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136, 374-384.
10. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014). Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344.
11. Aziz, N.A., Swaab, D.F., Pijl, H., and Roos, R.A. (2007). Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev. Neurosci. 18, 223-251.
12. Aziz, N.A., Pijl, H., Frolich, M., Snel, M., Streefland, T.C., Roelfsema, F., and Roos, R.A. (2010). Systemic energy homeostasis in Huntington's disease patients. J. Neurol. Neurosurg. Psychiatry 81, 1233-1237.
13. Baggio, L.L. and Drucker, D.J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157.
14. Baggio, L.L., Huang, Q., Brown, T.J., and Drucker, D.J. (2004). Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127, 546-558.
15. Bak, A.M., Egefjord, L., Gejl, M., Steffensen, C., Stecher, C.W., Smidt, K., Brock, B., and Rungby, J. (2011). Targeting Amyloid-β by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opin. Ther. Targets 15, 1153-1162.
16. Barnett, A.H. (2015). Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. Expert Opin. Drug Safety 14, 149-159.
17. Bataille, D., Tatemoto, K., Gespach, C., Jornvall, H., Rosselin, G., and Mutt, V. (1982). Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett. 146, 79-86.
18. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H., et al. (2008). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326-338.
19. Bhat, V.K., Kerr, B.D., Flatt, P.R., and Gault, V.A. (2013a). A novel GIPoxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem. Pharmacol. 85, 1655-1662.
20. Bhat, V.K., Kerr, B.D., Vasu, S., Flatt, P.R., and Gault, V.A. (2013b). A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia 56, 1417-1424.
21. Bianchi, E., Carrington, P.E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G., Kosinski, J., Marsh, D.J., Pocai, A., et al. (2013). A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorg. Med. Chem. 21, 7064-7073.
22. Bollag, R.J., Zhong, Q., Ding, K.H., Phillips, P., Zhong, L., Qin, F., Cranford, J., Mulloy, A.L., Cameron, R., and Isales, C.M. (2001). Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol. Cell. Endocrinol. 177, 35-41.
23. Bousquet, M., St-Amour, I., Vandal, M., Julien, P., Cicchetti, F., and Calon, F. (2012). High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol. Dis. 45, 529-538.
24. Brunetti, A., Chiefari, E., and Foti, D. (2014). Recent advances in the molecular genetics of type 2 diabetes mellitus. World J. Diabetes 5, 128-140.
25. Buhren, B.A., Gasis, M., Thorens, B., Muller, H.W., and Bosse, F. (2009). Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J. Neurosci. Res. 87, 1858-1870.
26. Cai, H., Cong, W.N., Ji, S., Rothman, S., Maudsley, S., and Martin, B. (2012). Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr. Alzheimer Res. 9, 5-17.
27. Campbell, J.E. and Drucker, D.J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837.
28. Cao, L., Li, D., Feng, P., Li, L., Xue, G.F., Li, G., and Holscher, C. (2016). A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuro Report 27, 384-391.
29. Cegla, J., Troke, R.C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K.A., Lim, C.T., Parvizi, N., Hussein, M., Chambers, E.S., et al. (2014). Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63, 3711-3720.
30. Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., and Pezzoli, G. (2011). Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care 34, 2614-2623.
31. Chaudhri, O.B., Parkinson, J.R., Kuo, Y.T., Druce, M.R., Herlihy, A.H., Bell, J.D., Dhillo, W.S., Stanley, S.A., Ghatei, M.A., and Bloom, S.R. (2006). Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem. Biophys. Res. Commun. 350, 298-306.
32. Chen, S., Liu, A.R., An, F.M., Yao, W.B., and Gao, X.D. (2012). Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr.) 34, 1211-1224.
33. Chen, X.W., He, Z.X., Zhou, Z.W., Yang, T., Zhang, X., Yang, Y.X., Duan, W., and Zhou, S.F. (2015a). Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 42, 999-1024.
34. Chen, Y., Zhang, Y., Li, L., and Holscher, C. (2015b). Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. Eur. J. Pharmacol. 768, 21-27.
35. Chen, Y., Zhang, J., Zhang, B., and Gong, C.X. (2016). Targeting insulin signaling for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 16, 485-492.
36. Chia, C.W., Carlson, O.D., Kim, W., Shin, Y.K., Charles, C.P., Kim, H.S., Melvin, D.L., and Egan, J.M. (2009). Exogenous glucosedependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58, 1342-1349.
37. Cho, Y.M., Merchant, C.E., and Kieffer, T.J. (2012). Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol. Ther. 135, 247-278.
38. Cicek, F.A., Tokcaer-Keskin, Z., Ozcinar, E., Bozkus, Y., Akcali, K.C., and Turan, B. (2014). Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation. Mol. Biol. Rep. 41, 4853-4863.
39. Cohen, A.D. and Klunk, W.E. (2014). Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol. Dis. 72 Pt A, 117-122.
40. Cork, S.C., Richards, J.E., Holt, M.K., Gribble, F.M., Reimann, F., and Trapp, S. (2015). Distribution and characterisation of glucagonlike peptide-1 receptor expressing cells in the mouse brain. Mol. Metab. 4, 718-731.
41. D'Amico, M., Di Filippo, C., Marfella, R., Abbatecola, A.M., Ferraraccio, F., Rossi, F., and Paolisso, G. (2010). Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol. 45, 202-207.
42. Dakin, C.L., Small, C.J., Batterham, R.L., Neary, N.M., Cohen, M.A., Patterson, M., Ghatei, M.A., and Bloom, S.R. (2004). Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145, 2687-2695.
43. Darsalia, V., Mansouri, S., Ortsater, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L.M., Grankvist, N., Sjoholm, A., et al. (2012). Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin. Sci. (Lond.) 122, 473-483.
44. Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nystrom, T., Sjoholm, A., Johansson, M.E., and Patrone, C. (2014). Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One 9, e103114.
45. Darsalia, V., Larsson, M., Lietzau, G., Nathanson, D., Nystrom, T., Klein, T., and Patrone, C. (2016). Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor. Diabetes Obes. Metab. 18, 537-541.
46. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., and Holst, J.J. (2000). Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85, 3575-3581.
47. Deacon, C.F., Danielsen, P., Klarskov, L., Olesen, M., and Holst, J.J. (2001). Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50, 1588-1597.
48. De Felice, F.G., Vieira, M.N., Bomfim, T.R., Decker, H., Velasco, P.T., Lambert, M.P., Viola, K.L., Zhao, W.Q., Ferreira, S.T., Kleina, WL. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc. Natl. Acad. Sci. USA. 106, 1971-1976.
49. Dong, J.Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D.F., and Taylor, J.E. (2011). Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. Diabetes Obes. Metab. 13, 19-25.
50. Doyle, M.E. and Egan, J.M. (2007). Mechanisms of action of glucagonlike peptide 1 in the pancreas. Pharmacol. Ther. 113, 546-593.
51. Dozier, K.C., Cureton, E.L., Kwan, R.O., Curran, B., Sadjadi, J., and Victorino, G.P. (2009). Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 30, 1735-1741.
52. 2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience 228, 294-300.
53. Dupre, J., Ross, S.A., Watson, D., and Brown, J.C. (1973). Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37, 826-828.
54. Dupuis, L., Dengler, R., Heneka, M.T., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Steiner, F., Lindauer, E., Otto, M., et al. (2012). A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 7, e37885.
55. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J., et al. (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173-1179.
56. Escribano, L., Simon, A.M., Gimeno, E., Cuadrado-Tejedor, M., Lopez de Maturana, R., Garcia-Osta, A., Ricobaraza, A., Perez-Mediavilla, A., Del Rio, J., and Frechilla, D. (2010). Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and pathology. Neuropsychopharmacology 35, 1593-1604.
57. 2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model. J. Alzheimers Dis. 35, 267-283.
58. 2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimers Res. Ther. 5, 20-28.
59. Faivre, E., Hamilton, A., and Holscher, C. (2012). Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur. J. Pharmacol. 674, 294-306.
60. Faludi, P., Brodows, R., Burger, J., Ivanyi, T., and Braun, D.K. (2009). The effect of exenatide re-exposure on safety and efficacy. Peptides 30, 1771-1774.
61. Farrer, L.A. (1985). Diabetes mellitus in Huntington disease. Clin. Genet. 27, 62-67.
62. Fatima, S., Haque, R., Jadiya, P., Shamsuzzama, Kumar, L., and Nazir, A. (2014). Ida-1, the Caenorhabditis elegans orthologue of mammalian diabetes autoantigen IA-2, potentially acts as a common modulator between Parkinson's disease and diabetes: role of Daf-2/Daf-16 insulin like signalling pathway. PLoS One 9, e113986.
63. Figueiredo, C.P., Antunes, V.L., Moreira, E.L., de Mello, N., Medeiros, R., Di Giunta, G., Lobao-Soares, B., Linhares, M., Lin, K., Mazzuco, T.L., et al. (2011). Glucose-dependent insulinotropic peptide receptor expression in the hippocampus and neocortex of mesial temporal lobe epilepsy patients and rats undergoing pilocarpine induced status epilepticus. Peptides 32, 781-789.
64. Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151.
65. Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36.
66. Finan, B., Muller, T.D., Clemmensen, C., Perez-Tilve, D., Di Marchi, R.D., and Tschop, M.H. (2016). Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22, 359-376.
67. Forst, T. and Pfutzner, A. (2012). Linagliptin, a dipeptidyl peptidase- 4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin. Pharmacother. 13, 101-110.
68. Freiherr, J., Hallschmid, M., Frey, W.H. 2nd, Brunner, Y.F., Chapman, C.D., Holscher, C., Craft, S., De Felice, F.G., and Benedict, C. (2013). Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505-514.
69. Gallwitz, B. (2013). Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab. Syndr. Obes. Targets Ther. 6, 1-9.
70. Gao, C., Holscher, C., Liu, Y., and Li, L. (2012). GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev. Neurosci. 23, 1-11.
71. Gao, C., Liu, Y., Jiang, Y., Ding, J., and Li, L. (2014). Geniposide ameliorates learning memory deficits, reduces phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced Alzheimer rat model. Brain Pathol. 24, 261-269.
72. Garg, K., Tripathi, C.D., and Kumar, S. (2013). Clinical review of sitagliptin: a DPP-4 inhibitor. J. Assoc. Physicians India 61, 645-649.
73. Gault, V.A. and Holscher, C. (2008a). GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by β-amyloid. Eur. J. Pharmacol. 587, 112-117.
74. Gault, V.A. and Holscher, C. (2008b). Protease-resistant glucosedependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by β-amyloid. J. Neurophysiol. 99, 1590-1595.
75. 1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J. 367, 913-920.
76. 2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J. Endocrinol. 176, 133-141.
77. 2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metab. Clin. Exp. 52, 679-687.
78. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54, 2436-2446.
79. Gault, V.A., Kerr, B.D., Irwin, N., and Flatt, P.R. (2008). C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem. Pharmacol. 75, 2325-2333.
80. Gault, V.A., Kerr, B.D., Harriott, P., and Flatt, P.R. (2011). Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin. Sci. (Lond.) 121, 107-117.
81. Gault, V.A., Bhat, V.K., Irwin, N., and Flatt, P.R. (2013). A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with tripleacting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J. Biol. Chem. 288, 35581-35591.
82. Gault, V.A., Lennox, R., and Flatt, P.R. (2015). Sitagliptin, a DPP-4 inhibitor, improves recognition memory, oxidative stress, hippocampal neurogenesis and up-regulates key genes involved in cognitive decline. Diabetes Obes. Metab. 7, 403-414.
83. Gejl, M., Gjedde, A., Egefjord, L., Moller, A., Hansen, S.B., Vang, K., Rodell, A.B., Braendgaard, H., Gottrup, H., Schacht, A., et al. (2016). Alzheimer's disease, six-month treatment with GLP-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front. Aging Neurosci. DOI: 10.3389/fnagi.2016.00108.
84. Gelling, R.W., Vuguin, P.M., Du, X.Q., Cui, L., Romer, J., Pederson, R.A., Leiser, M., Sorensen, H., Holst, J.J., Fledelius, C., et al. (2009). Pancreatic β-cell overexpression of the glucagon receptor gene results in enhanced β-cell function and mass. Am. J. Physiol. Endocrinol. Metab. 297, E695-E707.
85. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., and Holscher, C. (2012). Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33, 265-276.
86. Green, B.D., Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2005). A comparison of the cellular and biological properties of DPP-IVresistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Diabetes Obes. Metab. 7, 595-604.
87. Gupta, D., Peshavaria, M., Monga, N., Jetton, T.L., and Leahy, J.L. (2010). Physiologic and pharmacologic modulation of glucosedependent insulinotropic polypeptide (GIP) receptor expression in β-cells by peroxisome proliferator-activated receptor (PPAR)-g signaling: possible mechanism for the GIP resistance in type 2 diabetes. Diabetes 59, 1445-1450.
88. Hamilton, A. and Holscher, C. (2009). Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuro Report 20, 1161-1166.
89. Hamilton, A., Patterson, S., Porter, D., Gault, V.A., and Holscher, C. (2011). Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481-489.
90. Han, W.N., Holscher, C., Yuan, L., Yang, W., Wang, X.H., Wu, M.N., and Qi, J.S. (2013). Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats. Neurobiol. Aging 34, 576-588.
91. Han, L., Holscher, C., Xue, G.F., Li, G., and Li, D. (2016). A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. Neuro Report 27, 23-32.
92. Hansen, H.H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L.B., and Vrang, N. (2015). The GLP-1 receptor agonist liraglutide reduces pathology-specific phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 1634, 157-170.
93. Harkavyi, A. and Whitton, P.S. (2010). Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br. J. Pharmacol. 159, 495-501.
94. Harris, M.D., Davidson, M.B., and Rosenberg, C.S. (1986). Insulin antagonism is not a primary abnormality of amyotrophic lateral sclerosis but is related to disease severity. J. Clin. Endocrinol. Metab. 63, 41-46.
95. Hinke, S.A., Gelling, R.W., Pederson, R.A., Manhart, S., Nian, C., Demuth, H.U., and McIntosh, C.H. (2002). Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51, 652-661.
96. Hojberg, P.V., Vilsboll, T., Rabol, R., Knop, F.K., Bache, M., Krarup, T., Holst, J.J., and Madsbad, S. (2009). Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52, 199-207.
97. Holscher, C. (2011). Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem. Soc. Trans. 39, 891-897.
98. Holscher, C. (2014a). Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31-T41.
99. Holscher, C. (2014b). First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimers Dementia 10, S33-S37.
100. Holscher, C. (2014c). The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dementia 10, S47-S54.
101. Holscher, C. (2014d). Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem. Soc. Trans. 42, 593-599.
102. Holscher, C. and Li, L. (2010). New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol. Aging 31, 1495-1502.
103. Holst, J.J., Burcelin, R., and Nathanson, E. (2011). Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 27, 547-558.
104. Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., and Tuomilehto, J. (2007). Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30, 842-847.
105. Hunt, M.J. and Morton, A.J. (2005). Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res. 166, 220-229.
106. Hunter, K. and Holscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 13, 33-38.
107. Hurlbert, M.S., Zhou, W., Wasmeier, C., Kaddis, F.G., Hutton, J.C., and Freed, C.R. (1999). Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48, 649-651.
108. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., and Matthews, D.R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140-149.
109. Irwin, N. and Flatt, P.R. (2009). Therapeutic potential for GIP receptor agonists and antagonists. Best Pract. Res. Clin. Endocrinol. Metab. 23, 499-512.
110. Irwin, N. and Flatt, P.R. (2015). New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J. Diabetes 6, 1285-1295.
111. Irwin, N., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., and O'Harte, F.P. (2005a). Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol. Chem. 386, 679-687.
112. Irwin, N., Green, B.D., Gault, V.A., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., and O'Harte, F.P. (2005b). Degradation, insulin secretion, and antihyperglycemic actions of two palmitatederivatized N-terminal pyroglutamyl analogues of glucosedependent insulinotropic polypeptide. J. Med. Chem. 48, 1244-1250.
113. Irwin, N., O'Harte, F.P., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., and Flatt, P.R. (2006). GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J. Med. Chem. 49, 1047-1054.
114. Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., and Oka, J. (2006). Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci. Res. 55, 352-360.
115. Jain, S. and Sharma, B. (2015). Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiol. Behav. 152, 182-193.
116. Jawaid, A., Paganoni, S., Hauser, C., and Schulz, P.E. (2014). Trials of antidiabetic drugs in amyotrophic lateral sclerosis: proceed with caution? Neuro-degener. Dis. 13, 205-208.
117. Jendle, J., Martin, S.A., and Milicevic, Z. (2012). Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opin. Investig. Drugs 21, 1463-1474.
118. Ji, C., Xue, G.F., Li, G., Li, D., and Holscher, C. (2016a). Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease. Rev. Neurosci. 27, 61-70.
119. Ji, C., Xue, G.F., Lijun, C., Feng, P., Li, D., Li, L., Li, G., and Holscher, C. (2016b). A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res. 1634, 1-11.
120. Josefsen, K., Nielsen, M.D., Jorgensen, K.H., Bock, T., Norremolle, A., Sorensen, S.A., Naver, B., and Hasholt, L. (2008). Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J. Neuroendocrinol. 20, 165-172.
121. Jung, E., Kim, J., Kim, S.H., Kim, S., and Cho, M.H. (2014). Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur. J. Pharmacol. 744, 98-102.
122. Kaneb, H.M., Sharp, P.S., Rahmani-Kondori, N., and Wells, D.J. (2011). Metformin treatment has no beneficial effect in a doseresponse survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One 6, e24189.
123. Kappe, C., Tracy, L.M., Patrone, C., Iverfeldt, K., and Sjoholm, A. (2012). GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J. Neuroinflamm. 9, 276.
124. Kastin, A.J., Akerstrom, V., and Pan, W, (2002). Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18, 7-14.
125. Keating, G.M. (2015). Alogliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 75, 777-796.
126. 2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem. Pharmacol. 80, 1727-1735.
127. Kervran, A., Dubrasquet, M., Blache, P., Martinez, J., and Bataille, D. (1990). Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regul. Pept. 31, 41-52.
128. Kieffer, T.J., McIntosh, C.H., and Pederson, R.A. (1995). Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596.
129. Kielgast, U., Holst, J.J., and Madsbad, S. (2011). Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 60, 1599-1607.
130. Kim, S.J., Winter, K., Nian, C., Tsuneoka, M., Koda, Y., and McIntosh, C.H. (2005). Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic β-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J. Biol. Chem. 280, 22297-22307.
131. Kim, S., Moon, M., and Park, S. (2009). Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202, 431-439.
132. Kim, S.J., Nian, C., Karunakaran, S., Clee, S.M., Isales, C.M., and McIntosh, C.H. (2012). GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7, e40156.
133. Kim, S.H., Lee, S.H., and Yim, H.J. (2013). Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch. Pharm. Res. 36, 1185-1188.
134. Kimura, R., Okouchi, M., Fujioka, H., Ichiyanagi, A., Ryuge, F., Mizuno, T., Imaeda, K., Okayama, N., Kamiya, Y., Asai, K., et al. (2009). Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 162, 1212-1219.
135. Kopf, D. and Frolich, L. (2009). Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J. Alzheimers Dis. 16, 677-685.
136. Kosaraju, J., Gali, C.C., Khatwal, R.B., Dubala, A., Chinni, S., Holsinger, R.M., Madhunapantula, V.S., Muthureddy Nataraj, S.K., and Basavan, D. (2013a). Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 72, 291-300.
137. Kosaraju, J., Murthy, V., Khatwal, R.B., Dubala, A., Chinni, S., Muthureddy Nataraj, S.K., and Basavan, D. (2013b). Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol. 65, 1773-1784.
138. Kosaraju, J., Dubala, A., Chinni, S., Khatwal, R.B., Satish Kumar, M.N., and Basavan, D. (2014a). A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes. Pharm. Biol. 52, 268-271.
139. Kosaraju, J., Madhunapantula, S.V., Chinni, S., Khatwal, R.B., Dubala, A., Muthureddy Nataraj, S.K., and Basavan, D. (2014b). Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease. Behav. Brain Res. 267, 55-65.
140. Kosinski, J.R., Hubert, J., Carrington, P.E., Chicchi, G.G., Mu, J., Miller, C., Cao, J., Bianchi, E., Pessi, A., Sinharoy, R., et al. (2012). The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring) 20, 1566-1571.
141. Lalic, N.M., Maric, J., Svetel, M., Jotic, A., Stefanova, E., Lalic, K., Dragasevic, N., Milicic, T., Lukic, L., and Kostic, V.S. (2008). Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch. Neurol. 65, 476-480.
142. Lambeir, A.M., Durinx, C., Scharpe, S., and De Meester, I. (2003). Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294.
143. Lau, J., Bloch, P., Schaffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L.B., McGuire, J., Steensgaard, D.B., et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370-7380.
144. Lekoubou, A., Matsha, T.E., Sobngwi, E., and Kengne, A.P. (2014). Effects of diabetes mellitus on amyotrophic lateral sclerosis: a systematic review. BMC Res. Notes 7, 171.
145. Lester-Coll, N., Rivera, E.J., Soscia, S.J., Doiron, K., Wands, J.R., and de la Monte, S.M. (2006). Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 9, 13-33.
146. Li, L. and Holscher, C. (2007). Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384-402.
147. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., et al. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. USA. 106, 1285-1290.
148. Li, Y., Duffy, K.B., Ottinger, M.A., Ray, B., Bailey, J.A., Holloway, H.W., Tweedie, D., Perry, T., Mattson, M.P., Kapogiannis, D., et al. (2010a). GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19, 1205-1219.
149. Li, Y., Tweedie, D., Mattson, M.P., Holloway, H.W., and Greig, N.H. (2010b). Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113, 1621-1631.
150. Li, L., Zhang, Z.F., Holscher, C., Gao, C., Jiang, Y.H., and Liu, Y.Z. (2012a). (Val(8)) glucagon-like peptide-1 prevents hyperphos phorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur. J. Pharmacol. 674, 280-286.
151. Li, Y., Chigurupati, S., Holloway, H.W., Mughal, M., Tweedie, D., Bruestle, D.A., Mattson, M.P., Wang, Y., Harvey, B.K., Ray, B., et al. (2012b). Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 7, e32008.
152. Li, Y., Liu, W., Li, L., and Holscher, C. (2016). Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. Neuropharmacology 101, 255-263.
153. Lim, J.G., Lee, J.J., Park, S.H., Park, J.H., Kim, S.J., Cho, H.C., Baek, W.K., Kim, D.K., and Song, D.K. (2010). Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement. Neurosci. Lett. 479, 13-17.
154. Lima, M.M., Targa, A.D., Noseda, A.C., Rodrigues, L.S., Delattre, A.M., dos Santos, F.V., Fortes, M.H., Maturana, M.J., and Ferraz, A.C. (2014). Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? CNS Neurol. Disord. Drug Targets 13, 418-428.
155. Liu, Y.L., Ford, H.E., Druce, M.R., Minnion, J.S., Field, B.C., Shillito, J.C., Baxter, J., Murphy, K.G., Ghatei, M.A., and Bloom, S.R. (2010). Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int. J. Obes. (Lond.) 34, 1715-1725.
156. Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., and Holscher, C. (2015a). Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 303, 42-50.
157. Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Li, L., and Holscher, C. (2015b). Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. Eur. J. Pharmacol. 765, 284-290.
158. Long-Smith, C.M., Manning, S., McClean, P.L., Coakley, M.F., O'Halloran, D.J., Holscher, C., and O'Neill, C. (2013). The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromol. Med. 15, 102-114.
159. Luchsinger, J.A. (2012). Type 2 diabetes and cognitive impairment: linking mechanisms. J. Alzheimers Dis. 30 (Suppl 2), S185-S198.
160. Lund, A., Knop, F.K., and Vilsboll, T. (2014). Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Internal Med. 25, 407-414.
161. Lynch, A.M., Pathak, N., Flatt, Y.E., Gault, V.A., O'Harte, F.P., Irwin, N., and Flatt, P.R. (2014). Comparison of stability, cellular, glucose-lowering and appetite suppressing effects of oxyntomodulin analogues modified at the N-terminus. Eur. J. Pharmacol. 743, 69-78.
162. Ma, T.C., Buescher, J.L., Oatis, B., Funk, J.A., Nash, A.J., Carrier, R.L., and Hoyt, K.R. (2007). Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 411, 98-103.
163. Ma, Q.L., Yang, F., Rosario, E.R., Ubeda, O.J., Beech, W., Gant, D.J., Chen, P.P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009). β Amyloid oligomers induce phosphorylation of and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by ω 3 fatty acids and curcumin. J. Neurosci. 29, 9078-9089.
164. Maida, A., Lovshin, J.A., Baggio, L.L., and Drucker, D.J. (2008). The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β-cell function but does not inhibit gastric emptying in mice. Endocrinology 149, 5670-5678.
165. Marenah, L., McCluskey, J.T., Abdel-Wahab, Y.H., O'Harte, F.P., McClenaghan, N.H., and Flatt, P.R. (2006). A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biol. Chem. 387, 941-947.
166. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.M., Pierres, M., Nielsen, P.F., Ribel, U., Watanabe, T., Drucker, D.J., and Wagtmann, N. (2000). Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA. 97, 6874-6879.
167. Martin, B., Golden, E., Carlson, O.D., Pistell, P., Zhou, J., Kim, W., Frank, B.P., Thomas, S., Chadwick, W.A., Greig, N.H., et al. (2009). Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58, 318-328.
168. Martin, B., Chadwick, W., Cong, W.N., Pantaleo, N., Daimon, C.M., Golden, E.J., Becker, K.G., Wood, W.H. 3rd, Carlson, O.D., Egan, J.M., et al. (2012). Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy. J. Biol. Chem. 287, 31766-31782.
169. Matteucci, E. and Giampietro, O. (2015). Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors. Curr. Med. Chem. 22, 1573-1581.
170. Mazzocchi, G., Rebuffat, P., Meneghelli, V., Malendowicz, L.K., Tortorella, C., Gottardo, G., and Nussdorfer, G.G. (1999). Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway. Peptides 20, 589-594.
171. McClean, P.L. and Holscher, C. (2014a). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76, 57-67.
172. McClean, P.L. and Holscher, C. (2014b). Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 86C, 241-258.
173. McClean, P.L., Gault, V.A., Harriott, P., and Holscher, C. (2010). Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630, 158-162.
174. McClean, P.L., Parthsarathy, V., Faivre, E., and Holscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
175. McIntosh, C.H., Widenmaier, S., and Kim, S.J. (2009). Glucosedependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP). Vitam Horm 80, 409-471.
176. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., and Gallwitz, B. (2004). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662.
177. Mentlein, R. (1999). Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24.
178. Merchenthaler, I., Lane, M., and Shughrue, P. (1999). Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261-280.
179. Mikhail, N. (2008). Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 17, 845-853.
180. Miyake, Y., Tanaka, K., Fukushima, W., Sasaki, S., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., et al.; Fukuoka Kinki Parkinson's Disease Study G (2010). Casecontrol study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J. Neurol. Sci. 293, 82-86.
181. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., and O'Neill, C. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243.
182. Moran, L.B. and Graeber, M.B. (2008). Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 9, 1-13.
183. Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P.L., McGeer, E.G., and Hirayama, K. (1994). Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 87, 343-348.
184. Morris, J.K., Zhang, H., Gupte, A.A., Bomhoff, G.L., Stanford, J.A., and Geiger, P.C. (2008). Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1240, 185-195.
185. Morris, J.K., Bomhoff, G.L., Gorres, B.K., Davis, V.A., Kim, J., Lee, P.P., Brooks, W.M., Gerhardt, G.A., Geiger, P.C., and Stanford, J.A. (2011). Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 231, 171-180.
186. Mossello, E., Ballini, E., Boncinelli, M., Monami, M., Lonetto, G., Mello, A.M., Tarantini, F., Baldasseroni, S., Mannucci, E., and Marchionni, N. (2011). Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. Exp. Diabetes Res. 2011, 281674.
187. Muppidi, A., Zou, H., Yang, P.Y., Chao, E., Sherwood, L., Nunez, V., Woods, A.K., Schultz, P.G., Lin, Q., and Shen, W. (2016). Design of potent and proteolytically stable oxyntomodulin analogs. ACS Chem. Biol. 11, 324-328.
188. Nakamaru, Y., Hayashi, Y., Davies, M., Jurgen Heuer, H., Hisanaga, N., and Akimoto, K. (2015). Investigation of potential pharmacokinetic interactions between teneligliptin and metformin in steady-state conditions in healthy adults. Clin. Ther. 37, 2007-2018.
189. Nassar, N.N., Al-Shorbagy, M.Y., Arab, H.H., and Abdallah, D.M. (2015). Saxagliptin: a novel antiParkinsonian approach. Neuropharmacology 89C, 308-317.
190. Nauck, M.A. (2011). Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med. 124, S3-S18.
191. Nissen, A., Christensen, M., Knop, F.K., Vilsboll, T., Holst, J.J., and Hartmann, B. (2014). Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J. Clin. Endocrinol. Metab. 99, E2325-E2329.
192. Nyberg, J., Anderson, M.F., Meister, B., Alborn, A.M., Strom, A.K., Brederlau, A., Illerskog, A.C., Nilsson, O., Kieffer, T.J., Hietala, M.A., et al. (2005). Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J. Neurosci. 25, 1816-1825.
193. Nyberg, J., Jacobsson, C., Anderson, M.F., and Eriksson, P.S. (2007). Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J. Neurosci. Res. 85, 2099-2119.
194. 2-terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced antihyperglycemic activity. Diabetes 48, 758-765.
195. O'Harte, F.P., Mooney, M.H., Kelly, C.M., and Flatt, P.R. (2000). Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J. Endocrinol. 165, 639-648.
196. O'Harte, F.P., Gault, V.A., Parker, J.C., Harriott, P., Mooney, M.H., Bailey, C.J., and Flatt, P.R. (2002). Improved stability, insulinreleasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45, 1281-1291.
197. Ohshima, R., Hotsumi, K., Holscher, C., and Seki, K. (2015). Agerelated decrease in glucagon-like peptide-1 in mouse prefrontal cortex but not in hippocampus despite the preservation of its receptor. Am. J. Biosci. 1, 11-27.
198. Orskov, C., Wettergren, A., and Holst, J.J. (1996). Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31, 665-670.
199. Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., and Breteler, M.M. (1999). Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53, 1937-1942.
200. Parkinson, J.R., Chaudhri, O.B., Kuo, Y.T., Field, B.C., Herlihy, A.H., Dhillo, W.S., Ghatei, M.A., Bloom, S.R., and Bell, J.D. (2009). Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuro Image 44, 1022-1031.
201. Parthsarathy, V. and Holscher, C. (2013). The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur. J. Pharmacol. 700, 42-50.
202. Pathak, N.M., Pathak, V., Lynch, A.M., Irwin, N., Gault, V.A., and Flatt, P.R. (2015). Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice. Mol. Cell. Endocrinol. 412, 95-103.
203. Patil, S.P., Jain, P.D., Ghumatkar, P.J., Tambe, R., and Sathaye, S. (2014). Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 277, 747-754.
204. Patterson, M., Murphy, K.G., Patel, S.R., Patel, N.A., Greenwood, H.C., Cooke, J.H., Campbell, D., Bewick, G.A., Ghatei, M.A., and Bloom, S.R. (2009). Hypothalamic injection of oxyntomodulin suppresses circulating ghrelin-like immunoreactivity. Endocrinology 150, 3513-3520.
205. Perry, T.A. and Greig, N.H. (2004). A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 5, 565-571.
206. Perry, T., Haughey, N.J., Mattson, M.P., Egan, J.M., and Greig, N.H. (2002a). Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 302, 881-888.
207. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T., Egan, J.M., and Greig, N.H. (2002b). A novel neurotrophic property of glucagonlike peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958-966.
208. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., and Greig, N.H. (2003). Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J. Neurosci. Res. 72, 603-612.
209. Perurena, O.H. and Festoff, B.W. (1987). Reduction in insulin receptors in amyotrophic lateral sclerosis correlates with reduced insulin sensitivity. Neurology 37, 1375-1379.
210. Petersen, A. and Bjorkqvist, M. (2006). Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 24, 961-967.
211. Petersen, A.B. and Christensen, M. (2013). Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. Targets Ther. 6, 217-231.
212. Pintana, H., Apaijai, N., Chattipakorn, N., and Chattipakorn, S.C. (2013). DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 218, 1-11.
213. Pipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., and Chattipakorn, S.C. (2013). DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci. 37, 839-849.
214. Plosker, G.L. (2014). Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74, 223-242.
215. Pocai, A. (2014). Action and therapeutic potential of oxyntomodulin. Mol. Metab. 3, 241-251.
216. Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M.E., Jiang, G., et al. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258-2266.
217. Podolsky, S. and Leopold, N.A. (1977). Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23, 55-63.
218. Porter, D.W., Irwin, N., Flatt, P.R., Holscher, C., and Gault, V.A. (2011). Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur. J. Pharmacol. 650, 688-693.
219. Powers, W.J., Videen, T.O., Markham, J., McGee-Minnich, L., Antenor-Dorsey, J.V., Hershey, T., and Perlmutter, J.S. (2007). Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. USA. 104, 2945-2949.
220. Pradat, P.F., Bruneteau, G., Gordon, P.H., Dupuis, L., Bonnefont-Rousselot, D., Simon, D., Salachas, F., Corcia, P., Frochot, V., Lacorte, J.M., et al. (2010). Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 11, 166-171.
221. Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., and Whitton, P.S. (2012). Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46, 183-193.
222. Reimann, F. and Gribble, F.M. (2016). G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Diabetologia 59, 229-233.
223. Reyes, E.T., Perurena, O.H., Festoff, B.W., Jorgensen, R., and Moore, W.V. (1984). Insulin resistance in amyotrophic lateral sclerosis. J. Neurol. Sci. 63, 317-324.
224. Richter, B., Bandeira-Echtler, E., Bergerhoff, K., and Lerch, C. (2008). Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc. Health Risk Manage. 4, 753-768.
225. Ross, S.A., Brown, J.C., and Dupre, J. (1977). Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26, 525-529.
226. Sakurai, T. (2011). Incretin analogues as a novel treatment strategy for Alzheimer's disease. Nihon Rinsho Jpn. J. Clin. Med. 69, 848-852.
227. Salcedo, I., Tweedie, D., Li, Y., and Greig, N.H. (2012). Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharmacol. 166, 1586-1599.
228. Salhanick, A.I., Clairmont, K.B., Buckholz, T.M., Pellegrino, C.M., Ha, S., and Lumb, KJ. (2005). Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucosedependent insulinotropic polypeptide. Bioorg. Med. Chem. Lett. 15, 4114-4117.
229. Santiago, J.A. and Potashkin, J.A. (2013). Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176-186.
230. Scheen, A.J. (2016). Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev. Clin. Pharmacol. 9, 385-399.
231. Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., and Ritz, B. (2011). Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34, 1102-1108.
232. Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., and Carta, A.R. (2009). PPAR-γ-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 29, 954-963.
233. Schonberger, S.J., Jezdic, D., Faull, R.L., and Cooper, G.J. (2013). Proteomic analysis of the human brain in Huntington's disease indicates pathogenesis by molecular processes linked to other neurodegenerative diseases and to type-2 diabetes. J. Huntingtons Dis. 2, 89-99.
234. Seino, Y. and Yabe, D. (2013). Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J. Diabetes Invest. 4, 108-130.
235. Seufert, J. and Gallwitz, B. (2014). The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes. Metab. 16, 673-688.
236. Sharma, M., Jalewa, J., and Holscher, C. (2013). Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J. Neurochem. 128, 459-471.
237. Solmaz, V., Cinar, B.P., Yigitturk, G., Cavusoglu, T., Taskiran, D., and Erbas, O. (2015). Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur. J. Pharmacol. 765, 482-487.
238. 3)GIP-a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br. J. Pharmacol. 173, 27-38.
239. Sripetchwandee, J., Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., and Chattipakorn, S.C. (2014). DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats. Arch. Med. Res. 45, 547-552.
240. Sun, H., Knippenberg, S., Thau, N., Ragancokova, D., Korner, S., Huang, D., Dengler, R., Dohler, K., and Petri, S. (2013). Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell. Mol. Neurobiol. 33, 347-357.
241. Sun, Y., Lu, C.J., Chen, R.C., Hou, W.H., and Li, C.Y. (2015). Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J. Epidemiol. Jpn. Epidemiol. Assoc. 25, 445-451.
242. Takalo, M., Haapasalo, A., Martiskainen, H., Kurkinen, K.M., Koivisto, H., Miettinen, P., Khandelwal, V.K., Kemppainen, S., Kaminska, D., Makinen, P., et al. (2014). High-fat diet increases expression in the brain of T2DM and AD mice independently of peripheral metabolic status. J. Nutr. Biochem. 25, 634-641.
243. Takeda, H., Sasai, N., Ito, S., Obana, M., Takuma, T., Takai, M., Kaneshige, H., Machimura, H., Kanamori, A., Nakajima, K., et al. (2016). Efficacy and safety of alogliptin in patients with type 2 diabetes: analysis of the ATTAK-J Study. J. Clin. Med. Res. 8, 130-140.
244. Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., et al. (2012). Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338.
245. To, A.W., Ribe, E.M., Chuang, T.T., Schroeder, J.E., and Lovestone, S. (2011). The ϵ3 and ϵ4 alleles of human APOE differentially Affect phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One 6, e16991.
246. Tomkin, G.H. (2009). Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 11, 579-588.
247. Townsend, M., Mehta, T., and Selkoe, D.J. (2007). Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282, 33305-33312.
248. Trujillo, J.M. and Nuffer, W. (2014). Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann. Pharmacother. 48, 1494-1501.
249. Trumper, A., Trumper, K., and Horsch, D. (2002). Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells. J. Endocrinol. 174, 233-246.
250. Trumper, A., Trumper, K., Trusheim, H., Arnold, R., Goke, B., and Horsch, D. (2001). Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15, 1559-1570.
251. Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006). Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol. Endocrinol. 20, 1644-1651.
252. Vilsboll, T. (2009). Liraglutide: a new treatment for type 2 diabetes. Drugs Today 45, 101-113.
253. Vrang, N. and Larsen, P.J. (2010). Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog. Neurobiol. 92, 442-462.
254. Wang, X.H., Li, L., Holscher, C., Pan, Y.F., Chen, X.R., and Qi, J..S (2010). Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170, 1239-1248.
255. Wang, X.H., Yang, W., Holscher, C., Wang, Z.J., Cai, H.Y., Li, Q.S., and Qi, J.S. (2013). Val(8)-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats. J. Neurosci. Res. 91, 568-577.
256. Wynne, K., Park, A.J., Small, C.J., Patterson, M., Ellis, S.M., Murphy, K.G., Wren, A.M., Frost, G.S., Meeran, K., Ghatei, M.A., et al. (2005). Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54, 2390-2395.
257. Wynne, K., Park, A.J., Small, C.J., Meeran, K., Ghatei, M.A., Frost, G.S., and Bloom, S.R. (2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) 30, 1729-1736.
258. Xiong, H., Zheng, C., Wang, J., Song, J., Zhao, G., Shen, H., and Deng, Y. (2013). The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of and neurofilament proteins and insulin signaling pathways in mice. J. Alzheimers Dis. 37, 623-635.
259. Xiromerisiou, G., Hadjigeorgiou, G.M., Papadimitriou, A., Katsarogiannis, E., Gourbali, V., and Singleton, A.B. (2008). Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci. Lett. 436, 232-234.
260. Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., and Chen, H. (2011). Diabetes and risk of Parkinson's disease. Diabetes Care 34, 910-915.
261. Yang, H.K., Min, K.W., Park, S.W., Chung, C.H., Park, K.S., Choi, S.H., Song, K.H., Kim, D.M., Lee, M.K., Sung, Y.A., et al. (2015). A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes. Endocr. J. 62, 449-462.
262. Yarchoan, M., Toledo, J.B., Lee, E.B., Arvanitakis, Z., Kazi, H., Han, L.Y., Louneva, N., Lee, V.M., Kim, S.F., Trojanowski, J.Q., et al. (2014). Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with pathology in Alzheimer's disease and tauopathies. Acta Neuropathol. 128, 679-689.
263. Zhang, Y., Chen, Y., Li, L., and Holscher, C. (2015a). Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model. Behav. Brain Res. 293, 107-113.
264. Zhang, Y., Yin, F., Liu, J., Liu, Z., Guo, L., Xia, Z., and Zidichouski, J. (2015b). Geniposide attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease. Neurochem. Int. 89, 7-16.
265. Zhao, W.Q., De Felice, F.G., Fernandez, S., Chen, H., Lambert, M.P., Quon, M.J., Krafft, G.A., and Klein, W.L. (2008). Amyloid β oligomers induce impairment of neuronal insulin receptors. FASEB J. 22, 246-260.
266. Zhong, Q., Itokawa, T., Sridhar, S., Ding, K.H., Xie, D., Kang, B., Bollag, W.B., Bollag, R.J., Hamrick, M., Insogna, K., et al. (2007). Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am. J. Physiol. Endocrinol. Metab. 292, E543-E548.